Pharmaceuticals News and Research

RSS

Pharmaceuticals stored on space flights may have shorter shelf-life

Some of the Pharmaceuticals intended for the treatment of minor illnesses of astronauts in space may require special packaging and reformulation to remain stable for long periods in the space environment. That's according to Dr. Putcha and her colleagues from NASA, Johnson Space Centre. Their findings, published online in The AAPS Journal suggest that some of the pharmaceuticals stored on space flights may have shorter shelf-life than they do on Earth.

15 Apr 2011

Takeda announces EDARBI availability in U.S. pharmacies for hypertension treatment

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that EDARBI, an angiotensin II receptor blocker approved for the treatment of hypertension, or high blood pressure, is now available by prescription for adults in U.S. pharmacies.

15 Apr 2011

Quest PharmaTech, Hemispherx Biopharma enter clinical development arrangement

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.

15 Apr 2011

Novartis, Duke sign deal to develop pandemic flu vaccine

The Duke Human Vaccine Institute today announced a collaboration and strategic agreement with Novartis Vaccines and Diagnostics to enable the rapid development of a vaccine and accelerate preparedness in case of a pandemic virus threat such as pandemic influenza.

15 Apr 2011

FDA accepts Teva's NDA filing of Bio-T-Gel for male hypogonadism

BioSante Pharmaceuticals, Inc. today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva Pharmaceutical Industries Ltd.. The FDA has assigned a PDUFA date of November 14, 2011. The PDUFA date is the target date for the FDA to complete its review of the NDA.

15 Apr 2011

Major pharmaceutical company, Access sign deal for RNAi therapeutics

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

15 Apr 2011

Ortho-McNeil Neurologics announces voluntary recall of TOPAMAX 100mg Tablets

Ortho-McNeil Neurologics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., today announced it is voluntarily recalling two lots of TOPAMAX® (topiramate) 100mg Tablets. These two lots were shipped between 10/19/2010 and 12/28/2010 and distributed in the U.S. and Puerto Rico.

15 Apr 2011

Longer looks: Cities coping with aging populations; new apps for health

Robert Lustig is a specialist on pediatric hormone disorders and the leading expert in childhood obesity at the University of California, San Francisco, School of Medicine. … The viral success of his lecture, though, has little to do with Lustig's impressive credentials and far more with the persuasive case he makes that sugar is a "toxin" or a "poison," terms he uses together 13 times through the course of the lecture, in addition to the five references to sugar as merely "evil."

15 Apr 2011

EPO grants patent to OncoGenex OGX-427 for prostate cancer treatment

OncoGenex Pharmaceuticals, Inc., today announced that the European Patent Office has granted European Patent Number EP1545561 entitled "Oligonucleotides for Treatment of Prostate and other Cancers."

15 Apr 2011

RXi Pharmaceuticals acquires Apthera

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced the completion of its previously announced acquisition of Apthera, Inc.

15 Apr 2011

Simulations Plus announces release of MedChem Studio 2.0

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today the release of MedChem Studio™ version 2.0 with an impressive set of expanded and powerful capabilities for data mining and de novo molecule design.

12 Apr 2011

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva Pharmaceutical Industries Ltd. today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system products.

12 Apr 2011

Eagle and Cognizant partner with Pistoia Alliance for sequence services

Cognizant, a leading provider of consulting, technology, and business process outsourcing services, and Eagle Genomics Ltd., a bioinformatics software company specializing in genomic data management and integration, today announced they are working with the Pistoia Alliance, Inc., a nonprofit, precompetitive alliance of life science companies and vendors, as one of the groups engaged to develop a conceptual cloud-based platform to facilitate access to public and proprietary sources of gene sequence data.

12 Apr 2011

PharMEDium joins ASA as a valued corporate supporter

PharMEDium Healthcare Corporation has become an Industry Supporter of the American Society of Anesthesiologists, as a part of a new Corporate Supporter program available to pharmaceutical, medical device and practice management companies.

12 Apr 2011

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study of laquinimod, an oral, once-daily, investigational immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). These data will be presented as late-breaking research at the Annual Meeting of the American Academy of Neurology (AAN).

12 Apr 2011

Novel drug holds potential against resistant chronic myeloid leukemia

A study from Tufts Medical Center researchers published today finds that a novel drug shows promise for treating leukemia patients who have few other options because their disease has developed resistance to standard treatment.

12 Apr 2011

Nano Terra announces acquisition of Surface Logix

Nano Terra, Inc., a leading surface engineering and nanotechnology co-development company, today announced it is acquiring Surface Logix, Inc., a drug development company founded by renowned Harvard scientist Professor George Whitesides. Surface Logix has made significant breakthroughs in enhancing the molecular functionality of pharmaceuticals and advancing several drug candidates.

12 Apr 2011

Top-line results from DURECT's ELADUR Phase II trial in chronic low back pain

DURECT Corporation announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR, DURECT's proprietary investigational transdermal bupivacaine pain patch.

12 Apr 2011

Novelos Therapeutics acquires Cellectar

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that it has completed its acquisition of Cellectar, Inc., a Wisconsin-based drug development company, in a stock-for-stock transaction.

12 Apr 2011

Protest over planned cuts to Australian medical research funding

Australian medical researchers are protesting around the country following reports that funding to the sector could be cut in the May budget. The federal government is considering slashing $400 million from medical research.

11 Apr 2011